**TLR2, TLR4 AND MyD88 Mediate Allergic Airway Disease (AAD) and *Streptococcus pneumoniae*-Induced Suppression of AAD**

Alison N. Thorburn, Hsin-Yi Tseng, Chantal Donovan, Nicole G. Hansbro, Andrew G. Jarnicki, Paul S. Foster, Peter G. Gibson, Philip M. Hansbro*

The Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute and The University of Newcastle, Newcastle, New South Wales, Australia

* Philip.Hansbro@newcastle.edu.au

**Abstract**

**Background**

Exposure to non-pathogenic *Streptococcus pneumoniae* and vaccination are inversely associated with asthma. Studies in animal models demonstrate that airway administration of *S. pneumoniae* (live or killed), or its vaccines or components, suppresses the characteristic features of asthma in mouse models of allergic airway disease (AAD). These components could be developed into immunoregulatory therapies. *S. pneumoniae* components are recognized by Toll-like receptors (TLR) 2 and TLR4, and both induce inflammatory cell responses through the adaptor protein myeloid differentiation primary response gene 88 (MyD88). The involvement of TLR2, TLR4 and MyD88 in the pathogenesis of AAD and asthma is incompletely understood, and has not been studied in *S. pneumoniae*-mediated suppression of AAD. We investigated the role of TLR2, TLR4 and MyD88 in the development of AAD and *S. pneumoniae*-mediated suppression of AAD.

**Methods and Findings**

OVA-induced AAD and killed *S. pneumoniae*-mediated suppression of AAD were assessed in wild-type, TLR2<sup>-/-</sup>, TLR4<sup>-/-</sup>, TLR2/4<sup>-/-</sup> and MyD88<sup>-/-</sup> BALB/c mice. During OVA-induced AAD, TLR2, TLR4 and MyD88 were variously involved in promoting eosinophil accumulation in bronchoalveolar lavage fluid and blood, and T-helper type (Th)2 cytokine release from mediastinal lymph node T cells and splenocytes. However, all were required for the induction of airways hyperresponsiveness (AHR). In *S. pneumoniae*-mediated suppression of AAD, TLR2, TLR4 and MyD88 were variously involved in the suppression of eosinophilic and splenocyte Th2 responses but all were required for the reduction in AHR.

**Conclusions**

These results highlight important but complex roles for TLR2, TLR4 and MyD88 in promoting the development of OVA-induced AAD, but conversely in the *S. pneumoniae*-mediated suppression of AAD, with consistent and major contributions in both the induction and
suppression of AHR. Thus, TLR signaling is likely required for both the development of
asthma and the suppression of asthma by *S. pneumoniae*, and potentially other immuno-
regulatory therapies.

Introduction

Asthma is a chronic allergic airways disease (AAD) characterized by airway inflammation and
airway hyperresponsiveness (AHR). The incidence of asthma has increased dramatically over
the past three decades although disease incidence has now plateaued [1]. The reasons for the
increased incidence remain controversial, however, alterations in exposure to microbes during
the induction and development of the disease have been widely postulated to be involved [2, 3].
This potentially occurs through altered stimulation of the innate immune system. Pathogen
associated molecular patterns (PAMPs) are recognized by pattern recognition receptors
(PRRs) such as Toll-like receptors (TLRs). TLRs are expressed on antigen presenting cells, such
as macrophages and dendritic cells (DCs). TLR engagement leads to nuclear factor (NF)-κB
and/or interferon regulatory factor (IRF)3/7-induced production of inflammatory mediators
including TNFα, IL-1β, IL-6, IFNα/β and monocyte chemotactic protein (MCP)-1, which
attempt to control infection, as well as anti-inflammatory molecules such as IL-10 [4, 5]. TLR2
and TLR4 are two of the major TLRs involved in the recognition of major bacterial compo-
nents [6]. TLR engagement likely plays a major role in directing T cells responses and the
development of asthma. For example, a polymorphism in TLR2 has been associated with
asthma [7–9], and Hammad et al., showed that TLR4 expression on lung structural cells, but
not DCs, is necessary and sufficient for the induction of AAD [10]. However, much remains to
be uncovered of the role of TLRs in asthma pathogenesis. These studies have lead to the investi-
gation of modulating TLRs in asthma. Some have shown that TLR2 and TLR4 agonists may be
beneficial in asthma [2, 11, 12], whereas others show that some TLR4 agonists such as lipopoly-
saccharide (LPS) exacerbate disease [13]. Thus, there is a need to further investigate the contri-
bution of TLR responses in asthma and their potential for therapeutic modulation.

Several recent studies by us, and others, have highlighted the potential use of *S. pneumoniae*
as an immunoregulatory therapy for asthma [2, 14–19]. We have shown that *S. pneumoniae*
infection, whole killed bacteria, components, and vaccines suppress the characteristic features
of AAD in mice. This includes substantial reductions in eosinophil accumulation in bronchoal-
volar lavage fluid (BALF) and blood, Th2 cytokine release from mediastinal lymph nodes
(MLNs) and splenocytes and AHR [2, 14–19]. The mechanisms underlying suppression
involve the induction of regulatory T cells (Tregs) and the modulation of DCs and natural killer
T cells. However, the innate recognition pathways involved in *S. pneumoniae*-mediated sup-
pression of AAD that could be manipulated through the development of immunoregulatory
components of this bacterium have not been characterized.

The *S. pneumoniae* cell wall components lipoteichoic acid, lipopeptides and peptidoglycan
are recognized by TLR2 [20–22]. *S. pneumoniae* cell wall phosphorylcholine and the exotoxin,
puenolysin are recognized by TLR4 [23, 24], although there is some controversy. It is also
known that both TLR2 and TLR4 are involved in controlling *S. pneumoniae* infection and that
they play a partly overlapping and redundant roles [25]. In addition, the common TLR adapt-
protein myeloid differentiatation primary response gene 88 (MyD88) is absolutely required for
the control of the infection [26].
Since TLR2 and TLR4 are important in innate immunity and asthma, and recognize components of *S. pneumoniae*, we hypothesized that these receptors play an important role in the development of AAD and *S. pneumoniae*-mediated suppression of AAD. Here, we investigated the involvement of TLR2, TLR4 and MyD88, in ovalbumin (OVA)-induced AAD and *S. pneumoniae*-mediated suppression of disease features. We used wild type (Wt) mice and mice deficient (−/−) in TLR2, TLR4, TLR2 and 4, or MyD88, and assessed the development of AAD and whole killed *S. pneumoniae* (KSpn)-mediated suppression of AAD. We found that TLR2, TLR4 and MyD88 were variously important for the development of inflammation and AHR in OVA-induced AAD. Conversely we also found roles for TLR2, TLR4 and MyD88 in *S. pneumoniae*-mediated suppression of inflammation and AHR in AAD.

**Methods**

**Animals**

Six-eight week-old female BALB/c mice were obtained from the Animal Breeding Facility at The University of Newcastle. TLR2−/−, TLR4−/−, TLR2/4−/− and MyD88−/− mice on a BALB/c background were provided by the Australian National University (Canberra, Australia). All mice were maintained under specific pathogen free and controlled environmental conditions. Procedures were approved by the Animal Ethics Committee of The University of Newcastle.

**AAD**

The induction of AAD was performed using established techniques as previously described [17, 18, 27–29]. Mice were sensitized to OVA (i.p.; day 0; 50 μg; Sigma-Aldrich, St. Louis, MO) with Rehydragel (1 mg; Reheis, Berkeley Heights, NJ) in sterile saline (200 μl) (Fig 1A). Mice were challenged by intranasal (i.n.) droplet application of OVA (day 12–15; 10 μg in 50 μl sterile saline) under isofluorane anesthesia. Control mice received saline sensitization and OVA challenge. AAD was assessed on day 16.

**Ethanol-killed *S. pneumoniae***

During sensitization to OVA, mice were treated with ethanol-killed *S. pneumoniae* (2x10⁵ cfu) in sterile saline (30 μl; three doses 12 h apart) by intratracheal (i.t.) administration under intravenous alfaxan anesthesia as previously described (Fig 1A) [16].

**Real-time PCR**

For analysis of TLR2 and TLR4 gene expression, total RNA was prepared from whole lungs by TRIzol extraction and cDNA was generated. Real-time RT-PCR was performed as previously described [27, 30], with relative abundance determined by comparison with the reference gene hypoxanthine-guanine phosphoribosyltransferase. The following primer pairs were used: Tlr2 F: TGTAGGGGCTTCACTTCTCTGCTT, R: AGACTCCTGAGCAGAACAGCGTTT, Tlr4 F: ATGCATGGATCAGAACTCAGCAA, R: AAACCTTCCTGGGAAGAACTCTGG.

**Assessment of airway inflammation**

BALF was collected as previously described and differential leukocyte counts were determined from a total of 250 cells [31–33].
Blood collection

Whole blood was collected by cardiac puncture and blood smears prepared as previously described [19].

T-cell cytokine release

Single cell suspensions were prepared from mediastinal lymph nodes (MLNs) and spleens by pushing through 70 μm sieves and red blood cells lysed. Then 1 x 10^6 cells/well in 96 well U-bottomed plates were cultured in RPMI media supplemented with 10% FCS, HEPES (20 mM), penicillin/streptomycin (10 μg/ml), L-glutamine (2 mM), 2-mercaptoethanol (50 μM), sodium pyruvate (1 mM). Cells were stimulated with OVA (200 μg/ml) and cultured for 4 (MLNs) or 6 (spleen) days (5% CO_2, 37°C). Supernatants were collected and stored at -20°C until analysis. Cytokine concentrations in cell culture supernatants were determined by ELISA (BD Pharmingen, San Diego, CA) [19, 27].

AHR

AHR was assessed as previously described [34–36]. Briefly, anesthetized and tracheotomized mice were cannulated and connected to inline aerosol and ventilator apparatus. Changes in
airway function following challenge with increasing doses of aerosolized methacholine (1.25, 2.5, 5 and 10 mg/ml) were assessed by analysis of pressure and flow waveforms, and transpulmonary resistance and dynamic compliance were determined.

Data analysis
Data were analysed using GraphPad Prism (GraphPad Software, CA) and are represented as the mean ± the standard error of the mean (SEM). One-way ANOVA with Dunnett’s post-test was used to determine significance between data with multiple comparisons. Unpaired Student’s t-test was used to determine differences between two groups. One-way repeated measures ANOVA and Bonferroni’s post-test were used to determine significance for AHR data. $P < 0.05$ was considered statistically significant.

Results
Effects of AAD and administration of KSpn on TLR2 and TLR4 mRNA expression in the lung
In this study we used established models of OVA-induced AAD and KSpn-mediated suppression of AAD [16, 19]. We first assessed the expression of $Tlr2$ and $Tlr4$ mRNA in the lung tissues of Wt mice in these models. Mice were sensitized and challenged with OVA to induce AAD (Fig 1A). TLR mRNA expression during sensitization and after challenge was assessed. There were no changes in $Tlr2$ expression in AAD (OVA groups) compared to non-allergic (Saline) controls (Fig 1B and 1C). By contrast, $Tlr4$ expression increased 24 h after OVA sensitization but returned to control levels after airway challenges.

In S. pneumoniae-induced suppression of AAD, mice were treated with KSpn intratracheally then sensitized and challenged with OVA to induce AAD. The expression of $Tlr2$ significantly increased 24 h after KSpn treatment and OVA sensitization (KSpn/OVA), but not after challenge, compared to untreated allergic (OVA) controls (Fig 1B and 1C). In addition there were significant increases in $Tlr4$ expression following KSpn treatment and OVA sensitization, which was sustained after OVA challenge.

Roles of TLR2, TLR4 and MyD88 in AAD and KSpn-mediated suppression of eosinophils in BALF in AAD
We then assessed the contribution of TLR2 and TLR4 to AAD and KSpn-mediated suppression of AAD using TLR2$^{-/-}$, TLR4$^{-/-}$ and TLR2/4$^{-/-}$ mice. In addition, we used mice deficient in the TLR2 and TLR4 adapter protein MyD88 (MyD88$^{-/-}$). The induction of AAD was characterized by significant increases in the numbers of eosinophils in the BALF compared to the respective non-allergic controls, in all strains of mice (Fig 2A). Notably, the number of eosinophils in TLR4$^{-/-}$ mice was attenuated compared to Wt mice, indicating that the infiltration of these cells into BALF is partially dependent on TLR4.

As we have shown previously [16], the administration of KSpn led to a substantial and significant reduction in the number of eosinophils in the BALF of Wt mice with AAD compared to untreated Wt allergic controls. KSpn administration also partially but significantly reduced eosinophil infiltration into the airways of TLR2$^{-/-}$ mice compared to untreated TLR2$^{-/-}$ allergic controls. This indicates that TLR2 partially mediates the protective effects of KSpn on BALF eosinophils. However, administration of KSpn did not affect eosinophil infiltration in TLR4$^{-/-}$, TLR2/4$^{-/-}$ or MyD88$^{-/-}$ mice compared to their respective untreated allergic controls. Importantly nevertheless, the affect of KSpn on eosinophil infiltration in Wt mice was significantly greater than in TLR2$^{-/-}$, TLR4$^{-/-}$, TLR2/4$^{-/-}$ and MyD88$^{-/-}$ mice.
We also assessed the affects of TLR2, TLR4 and MyD88 on eosinophilia in the blood in AAD. AAD resulted in a significant increase in the percentage of eosinophils in the blood compared to the respective non-allergic controls, in all strains of mice (Fig 2B). However, the eosinophil percentage in MyD88−/− mice was attenuated compared to Wt mice. There was also a non-statistically significant trend toward less eosinophils in the blood of TLR4−/− and TLR2/4−/− mice.

Fig 2. Airway and blood eosinophilia in AAD and KSpn-induced suppression of AAD in MyD88 and TLR deficient mice. Six-week old BALB/c Wt, MyD88−/−, TLR2−/−, TLR4−/− and TLR2/4−/− mice were sensitized and challenged with OVA to induce AAD. Some groups were administered KSpn i.t. during sensitization. Eosinophil numbers in BALF (A) and percentage in blood (B) were determined. Data represent mean ± SEM, n = 8. Significance is represented by **P < 0.01, ***P < 0.001 (Saline v OVA groups of the same strain), #P < 0.05, ###P < 0.001 (OVA v KSpn+OVA groups of the same strain), †P < 0.05, ††P < 0.001 (Wt v −/− between OVA groups) and ‡P < 0.01, ‡‡P < 0.001 (Wt v −/− between KSpn+OVA groups).

Roles of TLR2, TLR4 and MyD88 in AAD and KSpn-mediated suppression of eosinophils in the blood in AAD

We also assessed the affects of TLR2, TLR4 and MyD88 on eosinophilia in the blood in AAD. AAD resulted in a significant increase in the percentage of eosinophils in the blood compared to the respective non-allergic controls, in all strains of mice (Fig 2B). However, the eosinophil percentage in MyD88−/− mice was attenuated compared to Wt mice. There was also a non-statistically significant trend toward less eosinophils in the blood of TLR4−/− and TLR2/4−/− mice.
As shown previously [16], administration of KSnp led to a significant reduction in eosinophil percentage in the blood of Wt mice compared to untreated Wt controls. Administration of KSnp also significantly reduced blood eosinophils in TLR2−/− and TLR2/4−/− mice compared to the respective untreated allergic controls. However, KSnp had no affect in TLR4−/− or MyD88−/− mice. Notably, assessment of TLR2/4−/− mice showed that TLRs were required for the suppression of eosinophils in BALF due to the absence of TLR4, and in the blood due to the absence of TLR2.

Roles of TLR2, TLR4 and MyD88 in AAD and KSnp-mediated suppression of IL-5 and IL-13 release from MLN T cells in AAD

We then assessed the contribution of TLR2, TLR4 and MyD88 on IL-5 and IL-13 release from MLN T cells in AAD and in KSnp-mediated suppression. AAD was characterized by significant increases in IL-5 and IL-13 release from MLN T cells compared to the respective non-allergic controls, in all strains of mice (Fig 3A and 3B). However, IL-5 levels were substantially attenuated in TLR2−/− mice. IL-13 levels were attenuated in MyD88−/− but actually increased in TLR2−/−, TLR4−/− and TLR2/4−/− mice compared to allergic Wt controls.

The administration of KSnp substantially suppressed IL-5 and IL-13 release from MLN T cells in all strains compared to their respective untreated allergic controls.

Roles of TLR2, TLR4 and MyD88 in AAD and KSnp-mediated suppression of systemic IL-5 and IL-13 release from splenocytes in AAD

We then assessed the contribution of TLR2, TLR4 and MyD88 to systemic IL-5 and IL-13 release from splenocytes in AAD and in KSnp-mediated suppression. AAD was characterized by increases in IL-5 and IL-13 release from splenocytes compared to the respective non-allergic controls in all strains of mice (Fig 4A and 4B). However, IL-5 levels were substantially attenuated in TLR2−/− and MyD88−/− mice compared to Wt allergic controls. IL-13 levels were also attenuated in TLR2−/− mice but in contrast were substantially increased in MyD88−/− mice.

As shown previously [16], administration of KSnp suppressed IL-5 and IL-13 release from splenocytes in allergic Wt mice compared to untreated allergic controls. KSnp also suppressed IL-5 and IL-13 release in TLR2−/− and MyD88−/− mice compared to their respective allergic controls. However, administration of KSnp had no affect on the release of these cytokines in TLR4−/− or TLR2/4−/− mice.

Roles of TLR2, TLR4 and MyD88 in AAD and KSnp-mediated suppression of AHR in AAD

To assess the contribution of TLR2, TLR4 and MyD88 to physiological outcomes in AAD we investigated their roles in AHR in AAD and in KSnp-mediated suppression.

AHR was measured in terms of airway resistance and dynamic compliance in response to increasing doses of methacholine. In non-allergic controls, airway responsiveness was attenuated in TLR2−/−, TLR4−/−, TLR2/4−/− and MyD88−/− compared to Wt mice (Fig 5A). When AAD-induced AHR was established, airway resistance and dynamic compliance were attenuated in all knockout mice compared to allergic Wt controls, with the exception of resistance in TLR4−/− mice (Fig 5B). Nevertheless, the development of AAD did lead to significant increases in airways resistance and decreases in dynamic compliance compared to the respective non-allergic control, in all strains.

Confirming our previous observations [16], administration of KSnp in AAD in Wt mice reduced AHR, significantly lowering airway resistance and increasing dynamic compliance to similar levels as the non-allergic controls (Fig 6A and 6B). In contrast, however, administration
of KSpn did not affect the development of AHR in TLR2-/-, TLR4-/-, TLR2/4-/- or MyD88-/- mice compared to their respective allergic controls.

**Discussion**

Here we demonstrate that TLR2, TLR4 and MyD88 are involved in the development of AAD, and conversely are also required for the suppression of AAD by exposure to bacteria/KSpn.
Each of these factors has a differential role in different situations. The induction of AAD lead to increases in eosinophils in BALF and blood, IL-5 and IL-13 production from MLNs and splenocytes, and AHR. Confirming our previous data [16], we again found that these features of AHR were suppressed by the administration of KSpn. We first detected substantial increases in Tlr2 and Tlr4 gene expression in the lung during KSpn-mediated suppression of AAD. Then in AAD we identified inductive roles for: TLR2 in IL-5 release from MLN T cells, IL-5 and IL-13 release from splenocytes and AHR; TLR4 in eosinophil infiltration into BALF and blood (partial) and AHR, and; MyD88 in blood eosinophilia, IL-13 release from MLN T cells and AHR (Fig 7). In addition, in the absence of both TLR2 and TLR4 there was actually an increase
in the release of IL-13 from MLN T cells. This is relevant since local IL-13 release can induce all of the features of AAD/asthma [37–39]. In KSpn-mediated suppression of AAD we identified important suppressive roles for: TLR2 in eosinophil infiltration into the airways (partial) and AHR; TLR4 in eosinophilia of the airways and blood, IL-5 and IL-13 release from splenocytes and AHR, and; MyD88 in airway and blood eosinophilia and AHR (Fig 7). Furthermore, data from TLR2/4-/- mice showed that both these TLRs were required for the suppression of eosinophils in BALF due to the absence of TLR4, and blood due to the absence of TLR2. Collectively, these data indicate that KSpn, and its components, can be used in immunoregulatory approaches to suppress AAD, which occurs through the induction of protective TLR responses. This provides further evidence for the use of these and other TLR agonists as asthma therapies [11].

Our analysis of mRNA expression in the lung in AAD showed that only that of Tlr4 mRNA was increased, and then only during sensitization. However, TLR2 and TLR4 mRNA expression was up-regulated by KSpn, which occurred during sensitization (Tlr2 and Tlr4) and challenge (Tlr4). This shows potential roles for TLR4 in allergic sensitization and that both these TLRs are involved in KSpn-mediated suppression of AAD. Furthermore, it indicates the existence of a positive feedback loop where KSpn-induced TLR engagement can lead to increased TLR expression that may be protective in AAD. This is known to occur with the TLR4 ligand lipopolysaccharide, which up-regulates TLR2 in a MyD88-dependent manner [40], and with

![Fig 5. Airway responsiveness at baseline and hyperresponsiveness in AAD in MyD88 and TLR deficient mice. Six-week old BALB/c Wt, MyD88-/-, TLR2-/-, TLR4-/- and TLR2/4-/- mice were sensitized and challenged with OVA to induce AAD. AHR in terms of airway resistance and dynamic compliance in saline sensitized mice (A). AHR in terms of airway resistance and dynamic compliance in OVA sensitized mice (B). Data represent mean ± SEM, n = 8. Significance is represented by §§P < 0.01, §§§P < 0.001 (Wt v -/- between Saline groups) and ††P < 0.01, †††P < 0.001 (Wt v -/- between OVA groups).](image-url)
Fig 6. Airway responsiveness at baseline and hyperresponsiveness in KSpn-induced suppression of AAD in MyD88 and TLR deficient mice. Six-week old BALB/c Wt, MyD88−/−, TLR2−/−, TLR4−/− and TLR2/4−/− mice were sensitized and challenged with OVA to induce AAD. Some groups were administered KSpn i.t. during sensitization. The effect of KSpn on AHR in terms of airway resistance and dynamic compliance in individual mouse strains (A) or combined for comparison (B). Data represent mean ± SEM, n = 8. Significance is represented by *P < 0.05, **P < 0.01, ***P < 0.001 (Saline v OVA groups of the same strain), ###P < 0.01 (OVA v KSpn+OVA groups of the same strain), ‡‡P < 0.01 (Wt v −/− between KSpn+OVA groups).

doi:10.1371/journal.pone.0156402.g006
the TLR2 ligand peptidoglycan that can up-regulate TLR2 expression \[41\]. TLR2 and TLR4 are expressed by DCs, macrophages, neutrophils, the airway epithelium and some subsets of Tregs, which implicates these cells in many processes that may be manipulated in TLR-directed therapies for AAD/asthma \[2, 6, 42, 43\].

**Fig 7. Role of TLRs in AAD and KSpn-mediated suppression.** In AAD TLR2 is involved in local IL-5 release from MLN T cells, the systemic release of IL-5 and IL-13 from splenocytes, and the induction of AHR (A). TLR4 is involved in eosinophil influx into the blood (partial) and airways, and the induction of AHR. The presence of either of these TLRs is required to control IL-13 production from MLNs. Many of these effects involve the TLR adaptor protein MyD88, which is required for blood eosinophilia, IL-13 release from MLN T cells and AHR. In KSpn-mediated suppression of AAD TLR2 is involved in the suppression of eosinophil infiltration into the airways and AHR (B). TLR4 is involved in the suppression of eosinophilia in the airways and blood, IL-5 and IL-13 release from splenocytes and AHR. Both TLRs are required for suppression of eosinophils in BALF due to the absence of TLR4, and blood due to the absence of TLR2. MyD88 is required for the suppression of airway and blood eosinophilia and AHR.

doi:10.1371/journal.pone.0156402.g007
This study shows that TLR2−/− mice with AAD had reduced IL-5 release from MLNs, IL-5 and IL-13 release from spleen and AHR compared to Wt. In KSpn-mediated suppression TLR2 was implicated in suppressing eosinophils in BALF (partial) and AHR. These outcomes demonstrate that the protective effects of KSpn are only partially dependent on TLR2. S. pneumoniae infection involves a TLR2 dependent crossing of the epithelial barrier to infect the lung [44]. Therefore in our study the protective effects of KSpn in AAD may not be as pronounced in TLR2−/− mice, because a lack of stimulation of the epithelium that is known to contribute to inflammatory responses in asthma [42]. The altered epithelial barrier in non-allergic TLR2−/− mice may explain why these mice are protected against airway responsiveness compared to non-allergic Wt mice.

TLR4−/− mice are protected against increases in BALF and blood (partial) eosinophils in AAD, highlighting that this receptor is required for eosinophil infiltration in AAD. The decreased levels of eosinophils are not due to reductions in IL-5 and IL-13. TLR4−/− mice have similar levels of airway resistance but increased dynamic compliance compared to Wt mice with AAD. In KSpn-mediated suppression TLR2 was implicated in suppressing blood and BALF eosinophils, splenic cytokine release and AHR. Local cytokine release was unaffected suggesting that the protective effects are systemic through as yet unknown mechanisms, potentially by inducing Tregs and modulating DCs in the periphery [18]. TLR2/4−/− mice with AAD had a trend to decrease eosinophils in BALF and similar decreased levels of eosinophils to TLR4−/− in blood, with evidence of AHR. Administration of KSpn had similar effects to those in TLR4−/− mice.

MyD88−/− mice treated with OVA had decreased eosinophils in BALF (trend) and blood, suggesting additional MyD88 actions that were independent of TLR2/4. MyD88−/− mice with AAD also had a small but significant decrease in IL-13 release from MLN T cells compared to Wt. They also had reduced IL-5 in splenocytes, contrasting with large increases in IL-13 release by splenocytes, and reduced AHR. This provides strong evidence that MyD88 is involved in the control of systemic IL-13 responses. In KSpn-mediated suppression MyD88 was implicated in protection against blood and BALF (partial) eosinophil levels. Our findings are consistent with a similar study that administered LPS/OVA to MyD88−/− mice and showed similar levels of eosinophils to MyD88−/−/OVA mice alone [45]. Given that S. pneumoniae has been shown to activate TLR2, TLR4 and TLR9, the protective effects of KSpn on AAD could be partly driven by a TLR9-MyD88 axis.

Our results with factor deficient mice highlight the differential involvement of TLRs in the development of OVA-induced AAD. Interestingly, the dependence on TLR2 for the induction of IL-5 release from MLN T cells and IL-5 and IL-13 from splenocytes were eliminated with the additional absence of TLR4 (i.e. in TLR2/4−/− mice). The reasons underlying this latter observation are unknown, however, it is likely that redundancy in signaling pathways may be occurring, which is revealed by the absence of both TLRs. Alternate signaling pathways may also be involved. TLR2 and TLR4 can use alternative adaptor proteins such as Toll/interleukin receptor domain-containing adapter-inducing IFN-β (TRIF) or MyD88 adaptor-like (Mal) [46, 47]. We showed further evidence for alternative signaling pathways when the induction of eosinophils in the BALF involved TLR4, but not TLR2 or MyD88. In the absence of MyD88, TLR4 signaling may occur through TRIF or Mal, although there have not as yet been any studies of the links between these other adaptor proteins and IL-5 or IL-13. Our data indicate that other factors may also be involved. In the absence of TLR2, MLN T cell and splenocyte release of IL-5 were reduced but there was no impact on eosinophilia in the BALF or blood. Also, generally in the TLR deficient mice MLN T cell IL-13 levels were increased but splenocyte IL-13 was decreased except for in MyD88−/− mice. This highlights the complexity of TLR responses, and indicates that they have overlapping or unique functions in different situations.
The use of isolated TLR agonists could be used to define their roles in AAD/asthma. Consistent with our findings that KSpn/OVA decreases eosinophils in a TLR2-dependent manner, a single study administered the TLR2/6 agonist, S-[2,3-bispalmitoyloxy-(2R)-propyl]-Rcysteinyl-amido-monomethoxy polyethylene glycol, conjugated with the antigen peptide (OVA) and challenged in a similar model, which reduced levels of IL-5 in the lung and eosinophils in BALF [48]. Others showed that lipoproteins from pathogenic S. pneumoniae induces TLR2 to promote the release of TNFα from macrophages during infection [49]. Another study demonstrated that administration of the TLR4 agonist, lipopolysaccharide (LPS), in a mouse model of OVA-induced AAD in Wt mice decreased IL-5 in MLN, IL-13 and eosinophils in the BALF eosinophils [45].

Our study used four strains of TLR/MyD88 deficient mice and compared the effects on AAD and KSpn-mediated suppression of AAD to Wt mice. For some measures the absence of these factors reduced or increased the development of features of AAD, which implicates their involvement in pathogenesis. Nevertheless there were still sufficient alterations in AAD features in factor deficient mice compared to non-allergic controls to enable the assessment of the impact of KSpn. Indeed in some cases KSpn reduced features of AAD in all strains (e.g. Fig 3).

Our data in combination with future TLR agonist, human and in vitro studies will facilitate the deciphering of the roles of TLRs in S. pneumoniae-mediated immunoregulation of AAD/asthma.

It is clear from our data that different TLRs have different effects and further investigations are needed to understand this. Clearly individual TLRs are needed for specific processes that are dependent on their known functions and signaling pathways. Collectively our data indicate that different TLRs have different effects in response to different agonists with TLR2 playing more of a role in the induction of AAD and TLR4 more involved in KSpn-mediated suppression. There is also likely to be redundancy, competing or overlapping effects that complicates the understanding of the requirement for each at different stages of the development of disease, i.e. sensitization vs. challenge, and during KSpn-mediated suppression. There is some divorce between the production of pro-AAD cytokines and eosinophil changes and AHR, suggesting that different features are affected at different time points and that different factors are involved. These issues may be addressed by assessing the roles of different factors at different time points and/or using mice in which TLR deficiency is inducible at various stages.

Other TLR or non-TLR pathways may also be involved in KSpn-mediated suppression of AAD. Certain features of AAD were still suppressed by KSpn in the absence of TLR2, TLR4 or MyD88. This again indicates that there may be redundancy in these signaling pathways, other mediators may be involved or that other completely different pathways may be important. For example, KSpn-mediated suppression of eosinophils required TLR4, but not MyD88 and, therefore, TLR4 is signaling through TRIF or Mal in this situation. The suppression of eosinophils in the blood required MyD88, but not TLR2 or TLR4, and may involve recognition by other MyD88-dependent TLRs such as TLR9, which recognizes bacterial DNA [50]. Suppression of IL-5 and IL-13 release from MLN T cells was not TLR or MyD88 dependent, however, suppression of cytokine release from splenocytes required TLR4 and not MyD88 and is likely to occur via TRIF.

The independent roles for TLR2 and TLR4 signaling pathways are likely driven by recognition of different KSpn components. Interestingly, TLR2, TLR4 and MyD88 were all required for KSpn-mediated suppression of AHR. This highlights a major involvement of these pathways, which are not redundant, in mediating the suppression of the major physiological precipitation of AAD. These data indicate that in these models AHR is independent of some features of inflammation, which has been shown previously [13]. Collectively, our results
show that KSpn-mediated suppression of AAD requires intact TLR2, TLR4 and MyD88 signaling pathways.

TLR2 and TLR4 are expressed by DCs, macrophages, neutrophils, the airway epithelium and some subsets of Tregs, which implicates them in many cellular processes that may be manipulated in TLR-directed therapies for AAD/asthma [2, 6, 42, 43]. Ultimately, TLR signaling can lead to changes in cellular function and pro- or anti-inflammatory responses. For instance, *S. pneumoniae*-induced signaling via TLR2 and TLR9 enhances phagocytosis and intracellular killing of the bacteria [51, 52]. TLR4 expression on DCs is important in directing Th2 cell responses and inflammation in OVA-induced AAD [43, 53, 54]. Furthermore, some TLR agonists induce anti-inflammatory responses by driving Treg responses [2, 55]. Notably, Tregs are known to be deficient in both number and function in asthmatics and also express TLRs such as TLR4 [2, 56]. Since, Treg are required for KSpn-mediated suppression of AAD and TLR4 is required for attenuation of some features of AAD, Treg expression of TLR4 could play a role in KSpn-mediated suppression of AAD and consequently asthma and this requires further investigation. In addition to circulating cells, the epithelium is now recognized to play a major role in initiating and contributing to Th2-induced responses [42]. Thus, epithelial TLR expression may have important consequences in directing immune responses. Indeed, infection with the bacteria *Klebsiella pneumoniae* up-regulates TLR2 and TLR4 on the airway epithelium [57]. The induction of TLR4 also induces the production of ICOS-expressing CD4 T cells, which can inhibit AAD in a mouse model [58]. Whether TLR4-induced ICOS on CD4 T cells is involved in KSpn-mediated suppression of AAD is unknown. Nevertheless, our studies, and those of others, highlight the important roles for TLR2 and TLR4 on multiple cell types in the orchestration of KSpn-mediated suppression of AAD, which requires further analysis.

In this study we used ethanol killed *S. pneumoniae*, which we previously showed suppresses AAD, and contains the TLR ligands, lipoteichoic acid, lipoproteins, peptidoglycan and pneumolysin, which are not destroyed by the alcohol [14]. The use of KSpn does not have the confounding impact of infection and heat killing destroys these TLR agonists. The use of KSpn was the first step in the development of an immunoregulatory therapy and contains all the components of the bacterium, which ensures that all relevant components are present. It is likely that where TLR2 is required for KSpn-mediated suppression, lipoteichoic acid, lipoproteins and peptidoglycan are the signal transducers. Where TLR4 is required, phosphorylcholine and pneumolysin may be the transducers. MyD88 is used by both TLR2 and TLR4 and, therefore, potentially by lipoteichoic acid, lipoproteins, peptidoglycan, phosphorylcholine and pneumolysin. Our data indicate that it is these combined TLR engagement events that are important in directing the multi-factorial KSpn-mediated suppression of AAD. We have recently identified two of the components of *S. pneumoniae* that are particularly important for suppressing AAD, i.e. the combination of polysaccharide and pneumolysoid (detoxified version of pneumolysin) [17]. In that study pneumolysoid (that signals via TLR4), was not effective at reducing features of AAD. However, cell wall components (containing TLR2 ligands) were shown to suppress AAD, suggesting that TLR2 signaling is required for the protective effects. These findings further indicate the importance of TLR2 and TLR4 signaling in mediating the suppressive effects of KSpn on AAD.

In future it will be interesting to extend our studies by investigating the roles of TLRs and impact of KSpn in house dust mite-induced models that involve sensitization direct through the airways. The differential contribution of innate signaling pathways on different cell compartments in AAD and KSpn-mediated suppression could also be investigated using tissue-specific deletion of TLRs or bone marrow chimera experiments as performed by Hammad et al., and us [10, 59]. It would also be interesting to assess the role of TLRs in infectious exacerbations of AAD using mouse models [60].
In summary, this study highlights major but complex roles for TLR2, TLR4 and MyD88 in the pathogenesis of AAD and in *S. pneumoniae*-mediated suppression of the disease. Each is important in AHR and in the suppression of AHR and there are distinct requirements for TLR2, TLR4 and MyD88 in the development and suppression of inflammation in AAD (Fig 7). We highlight that successful application of KSpn-mediated or other TLR-based immunoregulatory therapies would require patients to have intact TLR signaling pathways for the best outcome. In this regard, polymorphisms in TLR2 have been associated with asthma, implicating the importance of intact TLR signaling pathways [7]. Others have suggested that specific targeting of TLR4 could improve the efficacy of specific allergen immunotherapy [11, 12]. This has been shown with the TLR4 agonist monophosphoryl lipid (MPL), which has strong immunogenic effects and potential as an adjuvant for allergy vaccines [61]. Since KSpn, targets both TLR2 and TLR4, it may have increased potential for effective suppression of asthma, and *S. pneumoniae* components or vaccines, may have applicability as human therapies.

Acknowledgments

PMH was funded to perform these studies by The Hill family and the Asthma Foundation of NSW, and Australian Research Council (DP110101107) of Australia. PMH is supported by Research Fellowships from the NHMRC (1079187) and the Gladys Brawn Memorial Trust.

Author Contributions

Conceived and designed the experiments: ANT PSF PGG PMH. Performed the experiments: ANT HYT CD. Analyzed the data: ANT HYT CD. Wrote the paper: ANT HYT NGH AGJ PMH CD.

References

1. Beigelman A, Weinstock GM, Bacharier LB. The relationships between environmental bacterial exposure, airway bacterial colonization, and asthma. Current Opin Allergy Clin Immunol. 2014; 14(2):137–42.
2. Thorburn AN, Hansbro PM. Harnessing regulatory T cells to suppress asthma: From potential to therapy. Am J Respir Cell Mol Biol. 2010; 43(5):511–19. doi: 10.1165/rcmb.2009-0342TR PMID: 20997830
3. Thorburn AN, Macia L, Mackay CR. Diet, metabolites, and "Western-lifestyle" inflammatory diseases. Immunity 2014; 40(6):833–42. doi: 10.1016/j.immuni.2014.05.014 PMID: 2495023
4. Hu X, Chakravarty SD, Ivashkiv LB. Regulation of interferon and Toll-like receptor signaling during macrophage activation by opposing feedforward and feedback inhibition mechanisms. Immunol Rev 2008; 226(1):41–66.
5. Zhu J, Mohan C. Toll-like receptor signaling pathways—therapeutic opportunities. Mediators Inflamm. 2010; 2010:781235. doi: 10.1155/2010/781235 PMID: 20981241
6. Beckett EL, Phipps S, Starkey MR, Horvat JC, Beagley KW, Foster PS, et al. TLR2, but not TLR4, is required for effective host defence against *Chlamydia* respiratory tract infection in early life. PLOS One. 2012; 7(6):e39460. doi: 10.1371/journal.pone.0039460 PMID: 22724018
7. Bjornvold M, Munthe-Kaas MC, Egeland T, Joner G, Dahl-Jorgensen K, Njølstad P, et al. A TLR2 polymorphism is associated with type 1 diabetes and allergic asthma. Genes Immun. 2009; 10(2):181–87. doi: 10.1038/gene.2008.100 PMID: 19148143
8. Hollingsworth JW, Whitehead GS, Lin KL, Nakano H, Gunn MD, Schwartz DA, et al. TLR4 signaling attenuates ongoing allergic inflammation. J Immunol. 2006; 176(10):5856–62. PMID: 16670292
9. Tan AM, Chen HC, Pochard P, Eisenbarth SC, Herrick CA, Bottomly HK. TLR4 signaling in stromal cells is critical for the initiation of allergic Th2 responses to inhaled antigen. J Immunol. 2010; 184(7):3535–44. doi: 10.4049/jimmunol.0900940 PMID: 20194715
10. Hammad H, Chieppa M, Perros F, Willart MA, Germain RN, Lambrecht BN. House dust mite allergen induces asthma via TLR4 triggering of airway structural cells. Nat Med. 2009; 15(4):410–16. doi: 10.1038/nm.1946 PMID: 19330007
11. Velasco G, Campo M, Manrique OJ, Bellou A, He H, Arestides RS, et al. Toll-like receptor 4 or 2 ago-

12. 11.

13. 11.

Aryan Z, Holgate ST, Radzioch D, Rezaei N. A new era of targeting the ancient gatekeepers of the

14. 11.

15. 11.

16. 11.

17. 11.

18. 11.

19. 11.

20. 11.

21. 11.

22. 11.

23. 11.

24. 11.

25. 11.

26. 11.

27. 11.

28. 11.

29. 11.

mune system: Toll-like agonists in the treatment of allergic rhinitis and asthma. Int Arch Allergy Immu-

20. 11.

21. 11.

22. 11.

23. 11.

24. 11.

25. 11.

26. 11.

27. 11.

28. 11.

29. 11.

nol. 2015; 194(12):5838–50. doi: 10.4049/jimmunol.1500251 PMID: 25957171

20. 11.

21. 11.

22. 11.

23. 11.

24. 11.

25. 11.

26. 11.

27. 11.

28. 11.

29. 11.

2007; 25(48):8154–62. PMID: 17950502

20. 11.

21. 11.

22. 11.

23. 11.

24. 11.

25. 11.

26. 11.

27. 11.

28. 11.

29. 11.

2007; 37(1):53

20. 11.

21. 11.

22. 11.

23. 11.

24. 11.

25. 11.

26. 11.

27. 11.

28. 11.

29. 11.

20. 11.

21. 11.

22. 11.

23. 11.

24. 11.

25. 11.

26. 11.

27. 11.

28. 11.

29. 11.

20. 11.

21. 11.

22. 11.

23. 11.

24. 11.

25. 11.

26. 11.

27. 11.

28. 11.

29. 11.

70:458

50. doi:10.4049/jimmunol.1101299 PMID: 22461699

51. 11.

52. 11.

53. 11.

54. 11.

55. 11.

56. 11.

57. 11.

58. 11.

59. 11.

60. doi:10.1136/thx.2009.131508 PMID: 20965927

61. 11.

62. PMID:17950502

63. 11.

64. doi:10.1183/09031936.00049510 PMID: 17266740

65. 11.

66. PMID:12594207

67. 11.

68. PMID:15576672

69. 11.

70. 11.

71. 11.

72. 11.

73. 11.

74. 11.

75. 11.

76. 11.

77. 11.

78. 11.

79. 11.

80. 11.

81. 11.

82. 11.

83. 11.

84. 11.

85. 11.

86. 11.

87. 11.

88. 11.

89. 11.

90. 11.

91. 11.

92. 11.

93. 11.

94. PMID:12594207

95. 11.

96. PMID:10394090

97. 11.

98. PMID:17266740

99. doi:10.1136/thoraxjnl-2011-200160 PMID: 22387445

100. doi:10.4049/jimmunol.201232 PMID: 24048894

101. 11.

102. 11.

103. 11.

104. 11.

105. 11.

106. 11.

107. 11.

108. 11.

109. 11.

110. 11.

111. 11.

112. 11.

113. 11.

114. 11.

115. 11.

116. 11.

117. 11.

118. 11.

119. 11.

120. 11.

121. 11.

122. 11.

123. 11.

124. 11.

125. 11.

126. 11.

127. 11.

128. 11.

129. 11.

130. 11.

131. 11.

132. 11.

133. 11.

134. 11.

135. 11.

136. 11.

137. 11.

138. 11.

139. 11.

140. 11.

141. 11.

142. 11.

143. 11.

144. 11.

145. 11.

146. 11.

147. 11.

148. 11.

149. 11.

150. 11.

151. 11.

152. 11.

153. 11.

154. 11.

155. 11.

156. 11.

157. 11.

158. 11.

159. 11.

160. 11.

161. 11.

162. 11.

163. 11.

164. 11.

165. 11.

166. 11.

167. 11.

168. 11.

169. 11.

170. 11.

171. 11.

172. 11.

173. 11.

174. 11.

175. 11.

176. 11.

177. 11.

178. 11.

179. 11.

180. 11.

181. 11.

182. 11.

183. 11.

184. 11.

185. 11.

186. 11.

187. 11.

188. 11.

189. 11.

190. 11.

191. 11.

192. 11.

193. 11.

194. 11.

195. 11.

196. 11.

197. 11.

198. 11.

199. 11.

200. 11.

201. 11.

202. 11.

203. 11.

204. 11.
30. Horvat JC, Starkey MR, Kim Ry, Beagley KW, Preston JA, Gibson PG, et al. Chlamydial respiratory infection during allergen sensitization drives neutrophilic allergic airways disease. J Immunol. 2010; 184(8):4159–69. doi: 10.4049/jimmunol.0902287 PMID: 20228193

31. Hsu AC, Starkey MR, Hanish I, Parsons K, Haw TJ, Barr I, et al. Targeting PI3K-p110α suppresses influenza viral infection in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015; 191(9):1012–23. doi: 10.1164/rccm.201501-018OC PMID: 25751541

32. Asquith KL, Horvat JC, Kaiko GE, Carey AJ, Beagley KW, Hansbro PM et al. Interleukin-13 promotes susceptibility to chlamydial infection of the respiratory and genital tracts. PLOS Pathog 2011; 7:e1001339. doi: 10.1371/journal.ppat.1001339 PMID: 21573182

33. Tay HL, Kaiko GE, Plank M, Maltby S, Essilfie AT, Jarnicki AG, et al. Antagonism of miR-328 increases the antimicrobial function of macrophages and neutrophils and rapid clearance of non-typeable Haemophilus Influenzae (NTHi) from infected lung. PLOS Pathog. 2015; 11(4):e1004549. doi: 10.1371/journal.ppat.1004549 PMID: 25894560

34. Beckett EL, Stevens RL, Jarnicki AG, Kim RY, Hanish I, Hansbro NG, et al. A new short-term mouse model of chronic obstructive pulmonary disease identifies a role for mast cell tryptase in pathogenesis. J Allergy Clin Immunol. 2013; 131(3):752–62. doi: 10.1016/j.jaci.2012.11.053 PMID: 23380220

35. Horvat JC, Beagley KW, Wade MA, Preston JA, Hansbro NG, Hickey DK, et al. Neonatal chlamydial lung infection induces mixed T-cell responses that drive allergic airway disease. Am J Respir Crit Care Med. 2007; 176(6):556–64. PMID: 17600276

36. Hansbro PM, Hamilton MJ, Fricker M, Gellaty S, Jarnicki AG, Zheng D, et al. Importance of mast cell Prss31/transmembrane tryptase/tryptase-γ in lung function and experimental chronic obstructive pulmonary disease and colitis. J Biol Chem 2014; 289(26):18214–27. doi: 10.1074/jbc.M114.548594 PMID: 24821729

37. Horvat JC, Starkey MR, Kim Ry, Phipps S, Gibson PG, Beagley KW, et al. Early-life chlamydial lung infection enhances allergic airways disease through age-dependent differences in immunopathology. J Allergy Clin Immunol. 2010; 125(3):617–25. doi: 10.1016/j.jaci.2009.10.018 PMID: 20122715

38. Hansbro PM, Scott GV, Essilfie AT, Kim Ry, Starkey MR, Nguyen DH, et al. Th2 cytokine antagonists: potential treatments for severe asthma. Expert Opin Invest Drugs 2013; 22(1):49–69.

39. Starkey MR, Essilfie AT, Horvat JC, Kim Ry, Nguyen DH, Beagley KW, et al. Constitutive production of IL-13 promotes early-life Chlamydia respiratory infection and allergic airway disease. Mucosal Immunol. 2013; 6(3):569–79. doi: 10.1038/mi.2012.99 PMID: 23131786

40. Fan J, Frey RS, Malik AB. TLR4 signaling induces TLR2 expression in endothelial cells via neutrophil NADPH oxidase. J Clin Invest. 2003; 112(8):1234–43. PMID: 14561708

41. Liu Y, Wang Y, Yamakuchi M, Isowaki S, Nagata E, Kanmura Y, et al. Uproregulation of Toll-like receptor 2 gene expression in macrophage response to peptidoglycan and high concentration of lipopolysaccharide is involved in NF-kappa b activation. Infect Immun 2001; 69(5):2788–96. PMID: 11292690

42. Hallstrand TS, Hackett TL, Altemeier WA, Matute-Bello, Hansbro PM, Knight DA. Airway epithelial regulation of pulmonary immune homeostasis and inflammation. Clin Immunol. 2013; 151(1):1–15. doi: 10.1016/j.clim.2013.12.003 PMID: 24503171

43. Kaiko GE, Horvat JC, Beagley KW, Hansbro PM. Immunological decision-making: How does the immune system decide to mount a helper T-cell response? Immunology 2008; 123(3):326–38. PMID: 17983439

44. Clarke TB, Francella N, Huegel A, Weiser JN. Invasive bacterial pathogens exploit TLR-mediated downregulation of tight junction components to facilitate translocation across the epithelium. Cell Host Microbe 2011; 9(5):404–14. doi: 10.1016/j.chom.2011.04.012 PMID: 21575911

45. Bortolatto J, Borducchi E, Rodriguez D, Keller AC, Faquim-Mauro E, Bortoluci KR, et al. Toll-like receptor 4 agonists adsorbed to aluminium hydroxide adjuvant attenuate ovalbumin-specific allergic airway disease: role of MyD88 adaptor molecule and interleukin-12/interferon-γ axis. Clin Exp Allergy. 2008; 38(10):1668–79. doi: 10.1111/j.1365-2222.2008.03036.x PMID: 18631348

46. Hardy MP, McGGettrick AF, O’Neill LAJ. Transcriptional regulation of the human TRIF (TIR domain-containing adaptor protein inducing interferon beta) gene. Biochem J. 2004; 380(1):83–93.

47. Kenny EF, Talbot S, Gong M, Golenbock DT, Bryant CE, O’Neill LA. MyD88 adaptor-like is not essential for TLR2 signaling and inhibits signaling by TLR3. J Immunol 2009; 183(6):3642–51. doi: 10.4049/jimmunol.0901140 PMID: 19717524

48. Krishnaswamy JK, Jirmo AC, Baru AM, Ebensen T, Guzmán CA, Sparwasser T, et al. Toll-like receptor-2 agonist–allergen coupling efficiently redirects Th2 cell responses and inhibits allergic airway eosinophilia. Am J Respir Cell Mol Biol 2012; 47(6):852–63. doi: 10.1165/rcmb.2011-0414OC PMID: 22962064
49. Tomlinson G, Chimalapati S, Pollard T, Lapp T, Cohen J, Camberlein E, et al. TLR-mediated inflammatory responses to *Streptococcus pneumoniae* are highly dependent on surface expression of bacterial lipoproteins. J Immunol 2014; 193(7):3736–45. doi:10.4049/jimmunol.1401413 PMID: 25172490

50. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Shintaro Sato S, Sanjo H, et al. A Toll-like receptor recognizes bacterial DNA. Nature. 2000; 408:730–45.

51. Letiembre M, Echchannaoui H, Bachmann P, Ferracin F, Nieto C, Espinosa M, et al. Toll-like receptor 2 deficiency delays pneumococcal phagocytosis and impairs oxidative killing by granulocytes. Infect Immun. 2005; 73(12):8397–8401. PMID: 16299338

52. Albiger B, Dahlberg S, Sandgren A, Wartha F, Beiter K, Katsuragi H, et al. Toll-like receptor 9 acts at an early stage in host defence against pneumococcal infection. Cell Microbiol 2007; 9(3):633–44. PMID: 17004992

53. Eisenbarth SC, Piggott DA, Huleatt JW, Visintin I, Herrick CA, Bottomly K. Lipopolysaccharide-enhanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen. J Exp Med. 2002; 196(12):1645–51. PMID: 12486107

54. Kaiko GE, Phipps S, Hickey DK, Lam CE, Hansbro PM, Foster PS, et al. *Chlamydia muridarum* infection subverts dendritic cell function to promote Th2 immunity and airways hyperreactivity. J Immunol. 2008; 180(4):2225–32. PMID: 18250429

55. Conroy H, Marshall NA, Mills KH. TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. Oncogene 2008; 27(2):168–80. doi: 10.1038/sj.onc.1210910 PMID: 18176598

56. Caramalho I, Lopes-Carvalho T, Ostler D, Zelenay S, Haury M, Demengeot J. Regulatory T cells selectively express Toll-like receptors and are activated by lipopolysaccharide. J Exp Med. 2003; 197(4):403–11. PMID: 12591899

57. Regueiro V, Morante D, Campos MA, Margareto J, Garmendia J, Bengoechea JA. *Klebsiella pneumoniae* increases the levels of Toll-like receptors 2 and 4 in human airway epithelial cells. Infect Immun. 2009; 77(2):714–24. doi: 10.1128/IAI.00852-08 PMID: 19015258

58. Shalaby KH, Jo T, Nakada E, Allard-Coutu A, Tsuchiya K, Hirota N, et al. ICOS-expressing CD4 T cells induced via TLR4 in the nasal mucosa are capable of inhibiting experimental allergic asthma. J Immunol. 2012; 189(6):2793–2804. doi: 10.4049/jimmunol.1201194 PMID: 22908333

59. Starkey MR, Kim RY, Schilter HC, Shim D, Essilfie AT, Nguyen DH, et al. *Chlamydia muridarum* lung infection in infants alters hematopoietic cells to promote allergic airway disease in mice. PLOS One. 2012; 7(8):e42588. doi: 10.1371/journal.pone.0042588 PMID: 22870337

60. Starkey MR, Jarnicki AG, Essilfie AT, Gellatly SL, Kim RY, Brown AC, et al. Murine models of infectious exacerbations of airway inflammation. Curr Opin Pharmacol. 2013; 13(3):337–44. doi: 10.1016/j.coph.2013.03.005 PMID: 23566696

61. Puggioni F, Durham SR, Francis JN. Monophosphoryl lipid A (MPL) promotes allergen-induced immune deviation in favour of Th1 responses. Allergy 2005; 60(5):678–84. PMID: 15813815
